<![CDATA[ViiV Healthcare 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=34779>Fri, 01 May 2026 07:35:32 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023]]>https://www.newswire.co.kr/newsRead.php?no=976750Fri, 20 Oct 2023 09:30:00 +0900<![CDATA[ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV]]>https://www.newswire.co.kr/newsRead.php?no=956875Thu, 01 Dec 2022 09:40:00 +0900<![CDATA[ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period]]>https://www.newswire.co.kr/newsRead.php?no=941636Fri, 25 Mar 2022 09:40:44 +0900<![CDATA[ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention]]>https://www.newswire.co.kr/newsRead.php?no=936927Tue, 21 Dec 2021 17:00:00 +0900<![CDATA[미 FDA, 비브 헬스케어의 HIV 예방 지효성 주사제 ‘아프레투드’ 승인]]>https://www.newswire.co.kr/newsRead.php?no=936928Tue, 21 Dec 2021 17:00:00 +0900<![CDATA[ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs]]>https://www.newswire.co.kr/newsRead.php?no=927277Mon, 19 Jul 2021 10:30:00 +0900<![CDATA[ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment]]>https://www.newswire.co.kr/newsRead.php?no=917632Fri, 22 Jan 2021 10:57:48 +0900<![CDATA[ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV]]>https://www.newswire.co.kr/newsRead.php?no=902809Mon, 23 Mar 2020 11:07:22 +0900